Adaptimmune Therapeutics PLC (ADAP)
0.5866
0.00 (0.00%)
USD |
NASDAQ |
Nov 15, 16:00
0.586
0.00 (0.00%)
After-Hours: 20:00
Adaptimmune Therapeutics Research and Development Expense (TTM): 143.17M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 143.17M |
| June 30, 2024 | 146.65M |
| March 31, 2024 | 136.17M |
| December 31, 2023 | 126.51M |
| September 30, 2023 | 116.35M |
| June 30, 2023 | 111.75M |
| March 31, 2023 | 116.52M |
| December 31, 2022 | 127.73M |
| September 30, 2022 | 134.18M |
| June 30, 2022 | 129.21M |
| March 31, 2022 | 123.34M |
| December 31, 2021 | 111.09M |
| September 30, 2021 | 107.36M |
| June 30, 2021 | 103.22M |
| March 31, 2021 | 94.81M |
| December 31, 2020 | 91.57M |
| September 30, 2020 | 86.14M |
| June 30, 2020 | 91.70M |
| Date | Value |
|---|---|
| March 31, 2020 | 96.75M |
| December 31, 2019 | 97.50M |
| September 30, 2019 | 99.92M |
| June 30, 2019 | 93.78M |
| March 31, 2019 | 94.90M |
| December 31, 2018 | 98.61M |
| September 30, 2018 | 100.99M |
| June 30, 2018 | 101.54M |
| March 31, 2018 | 94.50M |
| December 31, 2017 | 87.39M |
| September 30, 2017 | 79.09M |
| June 30, 2017 | 70.66M |
| March 31, 2017 | 67.93M |
| December 31, 2016 | 63.79M |
| September 30, 2016 | 56.83M |
| June 30, 2016 | 46.22M |
| March 31, 2016 | 33.23M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
86.14M
Minimum
Sep 2020
146.65M
Maximum
Jun 2024
114.58M
Average
114.05M
Median
Research and Development Expense (TTM) Benchmarks
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | 35.08M |
| Autolus Therapeutics PLC | 129.68M |
| Bicycle Therapeutics PLC | 167.88M |
| TC BioPharm (Holdings) PLC | -- |